Nebula Research & Development LLC Has $1.82 Million Stock Position in Align Technology, Inc. (NASDAQ:ALGN)

Nebula Research & Development LLC increased its holdings in shares of Align Technology, Inc. (NASDAQ:ALGN) by 59.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 8,709 shares of the medical equipment provider’s stock after acquiring an additional 3,250 shares during the quarter. Nebula Research & Development LLC’s holdings in Align Technology were worth $1,816,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Picton Mahoney Asset Management raised its position in shares of Align Technology by 69.9% during the fourth quarter. Picton Mahoney Asset Management now owns 141 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 58 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in Align Technology during the 4th quarter worth approximately $31,000. Aster Capital Management DIFC Ltd bought a new position in Align Technology in the fourth quarter valued at approximately $35,000. Private Trust Co. NA boosted its holdings in shares of Align Technology by 113.4% in the fourth quarter. Private Trust Co. NA now owns 175 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 93 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of Align Technology by 212.2% during the fourth quarter. Versant Capital Management Inc now owns 231 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 157 shares in the last quarter. 88.43% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ALGN shares. Leerink Partners raised shares of Align Technology from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $235.00 to $280.00 in a research note on Monday, January 6th. Wells Fargo & Company started coverage on Align Technology in a research report on Friday, February 14th. They issued an “overweight” rating and a $255.00 target price on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Align Technology in a research note on Thursday, February 6th. Leerink Partnrs raised shares of Align Technology from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 6th. Finally, Evercore ISI raised their target price on shares of Align Technology from $240.00 to $260.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $246.17.

Align Technology Stock Down 0.5 %

Shares of NASDAQ ALGN opened at $183.35 on Friday. Align Technology, Inc. has a twelve month low of $141.74 and a twelve month high of $324.39. The company has a market cap of $13.42 billion, a PE ratio of 32.68, a price-to-earnings-growth ratio of 2.24 and a beta of 1.73. The business’s 50 day moving average price is $170.00 and its two-hundred day moving average price is $202.75.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.96 earnings per share for the quarter, missing analysts’ consensus estimates of $2.43 by ($0.47). Align Technology had a net margin of 10.54% and a return on equity of 13.84%. As a group, research analysts anticipate that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.